Pirfenidone Promising for RA-Linked Interstitial Lung Disease
Phase 2 trial terminated early, underpowered to meet primary end point, but limited results suggest pirfenidone may slow progression of RA-ILD
ACR: COVID-19 Vaccine Not Tied to Severe Rheumatic Disease Flares
Seropositivity lags after vaccination in those with rheumatic diseases but improves after second dose
COVID-19 Vaccines Seem Safe in Rheumatic, Musculoskeletal Disease Patients
Disease flare requiring treatment reported in 11 percent following two-dose mRNA SARS-CoV-2 vaccination, with no reports of severe flare
Methotrexate May Impair Immune Response to mRNA COVID-19 Vaccine
Poorer humoral, cellular immune responses seen in patients receiving methotrexate for immune-mediated inflammatory disease
Patients With RA Have Increased Anxiety During Pandemic
Anxiety during pandemic correlated with Health Assessment Questionnaire, biologic drug use, and previous anxiety point